News

MediPrint™ Ophthalmics Announces Successful Completion of Its SIGHT-1 Phase 2a Clinical Study

First-in-human Trial with Novel Glaucoma Treatment Confirmed Favorable Safety

Michael Jaramillo2021-03-24T16:15:38+00:0003.16.2021|

Leo Lens Pharma Announces A Corporate Name Change To MediPrint™ Ophthalmics

Araceli Richardson2021-03-24T16:08:46+00:0012.08.2020|

Leo Lens Pharma Achieves Two Significant Milestones – FDA IND Submission and Seed Round Fundraising Success

IND Paves the Way to Phase 2a Clinical Study

Araceli Richardson2021-03-24T16:21:17+00:0011.12.2020|

Leo Lens Pharma Expands Its Scientific Advisory Board

External Thought Leaders to Help Guide Progress on Company’s

Araceli Richardson2021-03-31T23:03:25+00:0008.05.2020|

Leo Lens Pharma Excited to be a Presenting Company at OTS 2020

Araceli Richardson2021-03-31T23:07:27+00:0007.17.2020|

Leo Lens Pharma Excited to Have Its Lead Asset Ready for Human Clinical Evaluation

Patented product for the novel treatment of glaucoma is

Araceli Richardson2021-03-31T23:08:42+00:0006.23.2020|

Leo Lens Pharma Proud to Be Selected as a Connect 2020 Cool Company

Araceli Richardson2021-03-31T23:12:15+00:0005.29.2020|

Leo Lens Pharma Appoints Dan Myers CEO

Accomplished Ophthalmic Executive to Lead Company in Its Next PhaseSAN

Araceli Richardson2021-03-31T23:13:40+00:0004.15.2020|

Myopia Management Focus of Pipeline Expansion for Leo Lens Pharma

Leo Lens Pharma Strengthens its Pipeline with New IP

Araceli Richardson2021-03-31T23:15:12+00:0002.20.2020|

Leo Lens Technology Selected as Finalist for Connect’s 2019 Most Innovative New Product Awards

FOR IMMEDIATE RELEASELeo Lens Technology Selected as Finalist for Connect’s

Araceli Richardson2021-03-31T23:16:14+00:0011.12.2019|